or Try an Advanced Search...

    Technical Analysis for CSTL - Castle Biosciences, Inc.

    Grade Last Price % Change Price Change
    D 21.19 -2.66% -0.58
    CSTL closed down 2.66 percent on Monday, July 1, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical CSTL trend table...
    Date Alert Name Type % Chg
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Stochastic Buy Signal Bullish 0.00%
    Inside Day Range Contraction 0.00%
    Oversold Stochastic Weakness 0.00%
    Pocket Pivot Bullish Swing Setup -2.66%
    Outside Day Range Expansion -2.66%
    Oversold Stochastic Weakness -2.66%
    NR7 Range Contraction 0.14%
    NR7-2 Range Contraction 0.14%
    Stochastic Reached Oversold Weakness 0.14%
    Older End-of-Day Signals for CSTL ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 6 hours ago
    60 Minute Opening Range Breakdown about 9 hours ago
    Down 3% about 9 hours ago
    Down 2 % about 9 hours ago
    10 DMA Resistance about 10 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CSTL Chart by TradingView
    Basic chart:

    Profile

    Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Medicine Cancer Clinical Medicine Melanoma Medical Test Gene Expression Metastasis Dsw Uveal Melanoma

    Is CSTL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 24 Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
    Jun 20 Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Jun 14 Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
    Jun 13 Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year?
    May 30 Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
    May 29 New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
    May 23 Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect?
    May 23 What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'
    May 15 Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
    May 14 Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
    See more CSTL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 25.91
    52 Week Low 12.07
    Average Volume 268,789
    200-Day Moving Average 20.31
    50-Day Moving Average 22.74
    20-Day Moving Average 22.32
    10-Day Moving Average 21.63
    Average True Range 1.00
    RSI (14) 41.52
    ADX 18.02
    +DI 16.78
    -DI 22.66
    Chandelier Exit (Long, 3 ATRs) 21.94
    Chandelier Exit (Short, 3 ATRs) 23.77
    Upper Bollinger Bands 24.08
    Lower Bollinger Band 20.56
    Percent B (%b) 0.18
    BandWidth 15.78
    MACD Line -0.51
    MACD Signal Line -0.38
    MACD Histogram -0.1342
    Fundamentals Value
    Market Cap 570.23 Million
    Num Shares 26.9 Million
    EPS -2.84
    Price-to-Earnings (P/E) Ratio -7.46
    Price-to-Sales 3.35
    Price-to-Book 1.67
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.35
    Resistance 3 (R3) 22.37 22.00 22.15
    Resistance 2 (R2) 22.00 21.71 21.99 22.09
    Resistance 1 (R1) 21.60 21.53 21.42 21.58 22.02
    Pivot Point 21.23 21.23 21.14 21.22 21.23
    Support 1 (S1) 20.83 20.94 20.65 20.81 20.36
    Support 2 (S2) 20.46 20.76 20.45 20.29
    Support 3 (S3) 20.06 20.46 20.23
    Support 4 (S4) 20.04